Start-ups
This section of our web site presents start-ups which have been created by DSV scientists, or which mainly exploit a DSV technology.
SPI-BIO, since its inception in 1991, has been promoting the enhanced value of the Pharmacology and Immunology research fields of the CEA. Therefore, SPI-BIO provides services and advices in pharmacology, pharmacokinetics, metabolism and analysis. In addition, SPI-BIO develops and markets immunological reagents and kits for xenobiotics and endogeneous molecules.
PartnerChip offers large scale services in genomics, trancriptomics, genotyping, for academics and industries.
IMSTAR S.A., a French based and privately owned Company founded in 1985, designs, manufactures and markets automated digital imaging systems for Life Sciences Research and Clinical departments in Cytogenetics, Pathology, Pharmaco-genomic, Drug Discovery and Validation.
Cisbio Bioassays is a company specialized in biomedical technologies. European leader in nuclear medicine, its field of expertise also covers the development of high-performance technologies for biomarkers and drug screening. The In Vitro Technologies Department is located in the South of France. Based on its know-how of monoclonal antiboby production through to end-product launching on the market, CISBIO offers a wide range of immunoassays for In Vitro Diagnostics.
PX'Therapeutics is a Contract Research and Manufacturing Organization dedicated to the development of biotherapeutics from early stage research up to cGMP production.
|
|
NatX-Ray is specialized in macromolecule crystallography and develops high throughput techniques especially for the Structural Genomics projects. NatX-ray can provide the equipment that implement these techniques, consummables, and can also offer a large panel of services that take advantage of these new techniques. |
|
|
Successfull Aging Edition is a bibliographical data base gathering recent scientific results regarding aging research and breakthroughs directed to a large community of lectors. |
HLA-G Technologies provides innovative products for unmet medical needs, particularly in transplantation, autoimmune diseases including psoriasis and cancer, and to conclude technological partnerships to support product development programs.
By detecting variations in immune signature and by assessing immune shield's quality during life, ImmunID Technologies permits the identification and characterization of immune dysfunction, the follow-up of disease progression and the measurement of immunotherapy efficiency.
|
|
Created in 2009, Vaxeal Therapeutics develops novel therapeutic vaccine strategies to address unmet medical needs in the field of infectious diseases and cancer. Its strategy resides in the restoration of appropriate immune responses in cancer and infected patients using selected immunogenic peptide sequences, called IRIC peptides for Immunoprevalence, Relevance, Intensity and Conservation. For each disease, IRIC sequences are selected on the basis of the molecular requisites for inducing protective responses. Vaxeal first focuses on hepatitis C and Malaria but cancer vaccines are under current development. |
Cytoo focuses on innovative products for the life science research market with an emphasis in cell based assays, high content analysis and cell screening
|
|
Fermentalg is a startup in the domain of White Biotech. It is dedicated to the high throughput screening of micro-algae strains, fermentation and extraction processes development of lipids and scale up for large industrialization. Products from Fermentalg research are of importance in the domains of aquaculture (algae biomass production), agronomy and cosmetics (omega 3, pigments…) and bioenergies. |
|
|
Promise is a spin-off company from the “Exploring the Dynamics of Proteomes” laboratory (EDyP, iRTSV) and holds an exclusive license to use the PSAQ™ method. Promise designs, promotes and implements innovative technologies to accompany and speed up the development of therapeutic proteins and biomarkers for a better health. |
